10
May
2022

MOMA Gets $150M to Make Small Molecules Against ATPases, Laborers of the Cell

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Clasp, Backed by Catalio, Third Rock & Novo, Gets $150M for Specific T-cell Engagers
MOMA Gets Roche Deal, $66M Upfront, to Discover Novel Small Molecule Cancer Drugs
Investing in the Future of Medicine: Reid Huber on The Long Run
Septerna, Backed by Third Rock and RA, Gets $150M for GPCR Drug Discovery